TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05897034
Drug: Nitazoxanide 500Mg Oral Tablet
Normalized name: Nitazoxanide 500mg Oral tablet
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
Study: NCT05158517
Drug: Subcutaneous vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
Study: NCT04935073
Drug: Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
Study: NCT05266417
Drug: INS-GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal INS-GSH Twice Daily
Study: NCT04467086
Drug: Propranolol Hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min.
Study: NCT05096065
Drug: Leuprolide Oral Tablet - 120 mg - QD- Treatment A
Normalized name: leuprolide acetate 120 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions.
Study: NCT05096065
Drug: Leuprolide Oral Tablet - 80 mg - QD - Treatment B
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Study: NCT05096065
Drug: Leuprolide Oral Tablet - 60 mg - QD - Treatment C
Normalized name: leuprolide acetate 60 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to 29 consecutive days with food-intake restrictions
Study: NCT05096065
Drug: Leuprolide Oral Tablet - 60 mg - BID - Treatment D
Normalized name: leuprolide acetate 60 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Study: NCT05096065
Drug: Leuprolide Oral Tablet - 40 mg - BID - Treatment E
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to 29 consecutive days with food-intake restrictions
Study: NCT05019417
Drug: Glycerol Phenylbutyrate 1100 MG/ML
Normalized name: glycerol phenylbutyrate 1100 MG/ML
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
Study: NCT05667454
Drug: Atropine Ophthalmic 0.5%
Normalized name: atropine ophthalmic 0.5% ophthalmic solution
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 0.5% sulphate ophthalmic solution
Study: NCT05781074
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PD-1 immune checkpoint inhibitor
Study: NCT05781074
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib capsules
Study: NCT05983471
Drug: ME-015 (Suplatast Tosilate)
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)
Study: NCT05045261
Drug: administration of SLGN in arm C
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of 3mg SLGN weekly for 24 weeks in arm C
Study: NCT04985721
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg orally twice a day
Study: NCT04985721
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV every 21 days
Study: NCT05379491
Drug: 3 L PEG + linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
Study: NCT05379491
Drug: 3 L PEG + placebo
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
Study: NCT05957328
Drug: Ferric Pyrophosphate Liposomal
Normalized name: ferric pyrophosphate liposomal
DrugBank: Ferric pyrophosphate (DB09147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
Study: NCT05957328
Drug: ferrous ascorbate
Normalized name: Ferrous ascorbate
DrugBank: Ferrous ascorbate (DB14490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
Study: NCT05064371
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concentrate for solution for IV infusion
Study: NCT05184517
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
Study: NCT05563272
Drug: 89Zr-DFO-girentuximab
Normalized name: DFO
DrugBank: Girentuximab (DB05304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
Study: NCT05287386
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Study: NCT05705466
Drug: Navtemadlin
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Study: NCT05705466
Drug: Navtemadlin Placebo
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
Study: NCT05705466
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
Study: NCT05254171
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel protein-bound particles for injectable suspension
Study: NCT05254171
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine for injection
Study: NCT05748236
Drug: Lamotrigine tablet
Normalized name: Lamotrigine Tablets
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
Study: NCT05748236
Drug: Carbamazepine-Containing Product in Oral Dose Form
Normalized name: Carbamazepine-containing product in oral dose form
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
Study: NCT04904536
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
Study: NCT06513806
Drug: Granisetron 1 Mg/mL Intravenous Solution
Normalized name: granisetron 1 mg/mL intravenous solution
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive granisetron 3 mg iv bolus
Study: NCT06513806
Drug: Pethidin
Normalized name: Pethidin
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive pethidine 25 mg iv bolus
Study: NCT05375825
Drug: LMB-100
Normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
Study: NCT05067387
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral THC (20 mg)
Study: NCT05067387
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral CBD (20 mg)
Study: NCT05165082
Drug: Timolol maleate 0.5% ophthalmic solution
Normalized name: Timolol Maleate 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply on affected finger or toes twice daily for 8 weeks
Study: NCT05325853
Drug: AG-920
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-920 Sterile Topical Ophthalmic Solution
Study: NCT00002394
Drug: Terbinafine hydrochloride
Normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00033163
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00033163
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04805073
Drug: Promethazine
Normalized name: Promethazine
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1cc 25mg/ml Promethazine (study medication)
Study: NCT05375240
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
Study: NCT05375240
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously 2.0g/day for 7 consecutive days.
Study: NCT06389578
Drug: Teprotumumab
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC administration and IV infusion
Study: NCT05677633
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Study: NCT04917731
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botox injected at digital artery
Study: NCT06041919
Drug: RESP301
Normalized name: RESP301
DrugBank: RESP301 (DB16497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide agent
Study: NCT06041919
Drug: HRZE
Normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
Study: NCT05062577
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sublingual
Study: NCT05172726
Drug: tapinarof cream, 1%
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied topically once daily
Study: NCT05817409
Drug: Intrathecal Baclofen Pump
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal baclofen treatment
Study: NCT05441267
Drug: Semaglutide Oral Tablet
Normalized name: semaglutide Oral Tablet
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Study: NCT05399329
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
Study: NCT05173896
Drug: Tadalafil 20 MG
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
Study: NCT04465734
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Study: NCT04465734
Drug: HLX04
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
Study: NCT04465734
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
Study: NCT05607953
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 doses are administered via PRVI using the PEDD method of administration
Study: NCT06726382
Drug: Esketamine Nasal Spray
Normalized name: esketamine Nasal Spray
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 28 mg dose
Study: NCT06726382
Drug: Esketamine 28 mg
Normalized name: esketamine 28 mg nasal spray
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 x 5,6 ml p.o.
Study: NCT06726382
Drug: Cobicistat 150 MG
Normalized name: cobicistat 150 MG
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 150 mg tablet
Study: NCT06725992
Drug: IY-NT-SR
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10mg
Study: NCT03915613
Drug: Humulin R
Normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study: NCT03915613
Drug: Diluent
Normalized name: Diluent
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study: NCT06725771
Drug: Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline
Normalized name: oyster shell calcium carbonate preparation
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
Study: NCT06725771
Drug: Sertraline Hydrochloride Tablets
Normalized name: Sertraline Hydrochloride Tablets
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline are given to patients simultaneously
Study: NCT05639257
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine tablets increasing dosis to maximal 300 mg daily
Study: NCT05639257
Drug: Namuscla
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Namuscla tablets increasing dosis to maximal 501 mg daily
Study: NCT06392633
Drug: Botulinum Toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
Study: NCT06187285
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient will get Empagliflozin 25
Study: NCT06187285
Drug: Sitagliptin 100mg
Normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient will get Sitagliptin 100 mg
Study: NCT05488925
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evion, 400 mg
Study: NCT06361758
Drug: Cadonilimab+Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
Study: NCT05618236
Drug: Group N; neostigmine+atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.